Reuters logo
Novo Nordisk says completes hemophilia drug trial
May 17, 2013 / 12:45 PM / 4 years ago

Novo Nordisk says completes hemophilia drug trial

COPENHAGEN (Reuters) - Denmark’s Novo Nordisk, the world’s biggest insulin producer, said on Friday it had completed the first phase III trial of a hemophilia drug, N9-GP.

Novo Nordisk said in a statement that in patients given the drug, 99 percent of bleeding episodes were treated with only one infusion and two-thirds of the patients had experienced complete resolution of bleeding.

Patients had also reported an improvement in quality of life during the trial and the drug appeared to have a safe and well-tolerated profile, Novo said in the statement.

Reporting by Copenhagen Newsroom; Editing by Anthony Barker

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below